MX365095B - Métodos y composiciones para incrementar la producción de ácido siálico y tratar condiciones de enfermedades relacionadas siálicas. - Google Patents

Métodos y composiciones para incrementar la producción de ácido siálico y tratar condiciones de enfermedades relacionadas siálicas.

Info

Publication number
MX365095B
MX365095B MX2013008948A MX2013008948A MX365095B MX 365095 B MX365095 B MX 365095B MX 2013008948 A MX2013008948 A MX 2013008948A MX 2013008948 A MX2013008948 A MX 2013008948A MX 365095 B MX365095 B MX 365095B
Authority
MX
Mexico
Prior art keywords
methods
gne
peptide
cell
nucleic acid
Prior art date
Application number
MX2013008948A
Other languages
English (en)
Other versions
MX2013008948A (es
Inventor
Daniel Darvish
Yadira Valles-Ayoub
Original Assignee
Hibm Res Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hibm Res Group Inc filed Critical Hibm Res Group Inc
Publication of MX2013008948A publication Critical patent/MX2013008948A/es
Publication of MX365095B publication Critical patent/MX365095B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
    • A61M5/425—Protruding skin to facilitate piercing, e.g. vacuum cylinders, vein immobilising means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe en el presente métodos para expresar péptido UDP-G1cNAc 2-Epimerasa/ManNAc enzima quinasa (GNE) en una célula de un sujeto que comprende: suministrar dentro de la célula del sujeto una construcción de expresión de ácido nucleico aislado que comprende un promotor unido operativamente a una secuencia de ácido nucleico que codifica un péptido GNE o un fragmento terapéuticamente activo del mismo, en donde el péptido GNE tiene la secuencia de ácido amino de SEQ ID NO:3, en donde en el suministro dentro de la célula del sujeto, la construcción de la expresión de ácido nucleico inicia la expresión del péptido GNE o un fragmento terapéuticamente activo. Asimismo, se describen métodos para producir péptido GNE en una célula que comprende la infección de la célula con una construcción del ácido nucleico aislado que comprende un promotor unido operativamente a una secuencia de ácido nucleico que codifica un péptido GNE o un fragmento terapéuticamente activo del mismo, en donde el péptido GNE tiene la secuencia de amino ácido de SEQ ID NO:3.
MX2013008948A 2011-02-01 2012-02-01 Métodos y composiciones para incrementar la producción de ácido siálico y tratar condiciones de enfermedades relacionadas siálicas. MX365095B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161438585P 2011-02-01 2011-02-01
PCT/US2012/023536 WO2012106465A2 (en) 2011-02-01 2012-02-01 Methods and compositions for increasing sialic acid production and treating sialic related disease conditions

Publications (2)

Publication Number Publication Date
MX2013008948A MX2013008948A (es) 2014-02-18
MX365095B true MX365095B (es) 2019-05-22

Family

ID=46603295

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008948A MX365095B (es) 2011-02-01 2012-02-01 Métodos y composiciones para incrementar la producción de ácido siálico y tratar condiciones de enfermedades relacionadas siálicas.

Country Status (9)

Country Link
US (2) US20130030040A1 (es)
EP (2) EP2670442A4 (es)
JP (2) JP2014506787A (es)
KR (2) KR20140034150A (es)
AU (2) AU2012212162A1 (es)
CA (1) CA2863578C (es)
IL (1) IL227773B (es)
MX (1) MX365095B (es)
WO (1) WO2012106465A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057856A1 (en) * 2012-08-22 2014-02-27 The Regents Of The Universtiy Of California Compositions and Methods For Enhancing Sialic Acid Levels In Tissue
US20150322439A1 (en) * 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression
US20140256638A1 (en) * 2013-02-14 2014-09-11 The Regents Of The University Of California Peptoid neutralizing agents
CN103088090B (zh) * 2013-03-01 2014-06-04 南京工业大学 一种n-乙酰葡萄糖胺异构酶在生产n-乙酰甘露糖胺中的应用
EP3218005B1 (en) 2014-11-12 2023-01-04 Seagen Inc. Glycan-interacting compounds and methods of use
EP3373969A4 (en) 2015-11-12 2019-08-14 Siamab Therapeutics, Inc. GLYCANINTERAGING COMPOUNDS AND METHOD OF USE
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
CN108285886A (zh) * 2018-01-30 2018-07-17 江南大学 重组枯草芽孢杆菌全细胞转化生产n-乙酰神经氨酸的方法
US11865165B2 (en) 2018-09-18 2024-01-09 Daniel DARVISH GNE as a therapeutic agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173465A9 (en) 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
WO2001059075A1 (en) * 2000-02-08 2001-08-16 Genentech, Inc. Improved sialylation of glycoproteins
US20060218669A1 (en) * 2003-02-11 2006-09-28 Lokesh Joshi Sialylation of glycoproteins in plants
WO2005030292A2 (en) * 2003-09-26 2005-04-07 The Trustees Of The University Of Pennsylvania Methods, compositions and apparatus for delivering heterologous molecules to cells
WO2008001023A1 (en) 2006-06-27 2008-01-03 Gigabeam Corporation Cellular communication system
WO2008097623A2 (en) * 2007-02-07 2008-08-14 Gradalis, Inc. Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
US9217020B2 (en) 2007-04-17 2015-12-22 National Research Council Of Canada Constructs for enhancement of gene expression in muscle
US9018174B2 (en) * 2008-05-28 2015-04-28 Hibm Research Group, Inc. Mouse model and treatment of hereditary inclusion body myopathy
EP2324110A4 (en) 2008-09-09 2013-01-09 Univ California REMOVAL OF NON-HUMAN SIALIC ACID CONTAMINATED BY METABOLIC COMPETITION
US9045759B2 (en) * 2009-01-21 2015-06-02 James Arthur Williams DNA plasmids with improved copy number
US8940876B2 (en) * 2010-02-08 2015-01-27 Korea Advanced Institute Of Science And Technology Method for preparing recombinant glycoproteins with high sialic acid content

Also Published As

Publication number Publication date
KR20140034150A (ko) 2014-03-19
WO2012106465A2 (en) 2012-08-09
AU2012212162A1 (en) 2013-08-29
MX2013008948A (es) 2014-02-18
US20140275230A1 (en) 2014-09-18
AU2017203027B2 (en) 2019-08-15
EP2670442A4 (en) 2015-07-29
KR20190108178A (ko) 2019-09-23
EP3202425A1 (en) 2017-08-09
IL227773A0 (en) 2013-09-30
JP2017158577A (ja) 2017-09-14
CA2863578C (en) 2021-10-26
AU2017203027A1 (en) 2017-07-20
EP2670442A2 (en) 2013-12-11
US10098969B2 (en) 2018-10-16
WO2012106465A3 (en) 2014-04-24
CA2863578A1 (en) 2012-08-09
KR102257741B1 (ko) 2021-05-28
US20130030040A1 (en) 2013-01-31
IL227773B (en) 2021-03-25
JP2014506787A (ja) 2014-03-20

Similar Documents

Publication Publication Date Title
CA2863578C (en) Methods and compositions for increasing sialic acid production and treating sialic related disease conditions
MY160897A (en) Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
MY176331A (en) Carbohydrate degrading polypeptide and uses thereof
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
IN2012DN01652A (es)
IN2014CN01706A (es)
EA201300054A1 (ru) Полипептид, обладающий активностью бета-глюкозидазы, и его применение
EA201201126A1 (ru) Полипептид, обладающий активностью целлобиогидролазы, и его применение
NZ604915A (en) Recombinant production of steviol glycosides
MX2010009465A (es) Una celula fermentadora de azucar pentosa.
NZ598351A (en) Il-17 binding compounds and medical uses thereof
NZ595501A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
NZ718173A (en) Clostridium histolyticum enzymes and methods for the use thereof
NZ596660A (en) Dig-5 insecticidal cry toxins
NZ742660A (en) Variants of chymosin with improved milk-clotting properties
MX2016009149A (es) Variantes mejoradas de enzimas.
MY185050A (en) A pentose sugar fermenting cell
MX2010009809A (es) Una celula fermentadora de azucar pentosa.
EA201300057A1 (ru) Полипептид, обладающий углеводдеградирующей активностью, и его применения
WO2013093029A3 (en) Variants of yeast ndi1 gene, and uses thereof in the treatment of disease associated with mitochondrial dysfunction
MY170467A (en) High molecular weight pha-producing microbe and method of producing high molecular weight pha using same
IN2015DN02650A (es)
NZ709120A (en) Beta-hexosyl-transferases and uses thereof
EA201300059A1 (ru) Полипептид, обладающий активностью сволленина, и его применение
WO2013052814A8 (en) E1 enzyme mutants and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration